SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

SNDL Inc.NASDAQ: SNDL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 27.0%

Gross margin was 27.0% in Q1 FY2026, down 0.7 pp from a year earlier. On a trailing-twelve-month basis it was 27.2%, up 0.6 pp year over year. Over 3 fiscal years it widened by 7.6 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
27.0%-0.9 pp QoQ
Last fiscal yearDec 2025
27.3%+1.2 pp YoY
LTMMar 2026
27.2%+0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.7 pp——
1 year+1.2 pp——
3 years+7.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
27.3%
Year-over-year change
+1.2pp

Gross Margin vs competitors

How SNDL compares with its peers on the latest reported figures

  • SNDL's LTM Mar 2026 gross margin of 27.2% is the lowest of the 8 companies compared; the peer median is 65.4%.
  • Its year-over-year change of +0.6 pp is the 3rd highest of 8, against a peer median of -2.3 pp.
  • Over three fiscal years its change of +7.6 pp compares with a peer median of +2.1 pp.
SNDL Competitors Peer median
Gross Margin for SNDL and competitors
Company Period LTM level YoY 3-year change
AKBAAkebia Therapeutics, Inc.LTM Mar 202680.9% +8.2 pp-9.0 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
EOLSEvolus, Inc.LTM Mar 202665.5% -2.3 pp+4.5 pp
SIGASIGA Technologies, Inc.LTM Mar 202665.4% -11.2 pp-22.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 202665.0% -0.3 pp+3.7 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
SNDLSNDL Inc.LTM Mar 202627.2% +0.6 pp+7.6 pp
CMPSCOMPASS Pathways plcFY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SNDL) 65.4%-2.3 pp+2.1 pp

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.